Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy.
Arndt C, Tunger A, Wehner R, Rothe R, Kourtellari E, Luttosch S, Hannemann K, Koristka S, Loureiro LR, Feldmann A, Tonn T, Link T, Kuhlmann JD, Wimberger P, Bachmann MP, Schmitz M.
Arndt C, et al. Among authors: rothe r.
Front Pharmacol. 2023 Feb 3;14:970457. doi: 10.3389/fphar.2023.970457. eCollection 2023.
Front Pharmacol. 2023.
PMID: 36817127
Free PMC article.